Injectable Fosnetupitant Formulation With pH-Balanced Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Fosnetupitant formulations face challenges with degradation, solubility issues, and bioavailability problems, requiring stable and soluble injectable solutions that avoid harmful additives and maintain stability under varying environmental conditions.
Innovation Solution
Lyophilized and liquid formulations of fosnetupitant are developed with balanced ratios of fosnetupitant and netupitant, adjusted pH, and specific excipients like disodium edetate to ensure stability and solubility, avoiding degradation and injection site reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fosnetupitant is formulated as an injectable solution, then bioavailability is improved, but stability and solubility deteriorate due to degradation and precipitation
Solution Approach 1:
The patent applies parameter changes by adjusting the pH of the injectable formulation to a specific range (pH 7.0-10.0, preferably pH 7.5-9.5) to optimize both solubility and stability of fosnetupitant. This pH adjustment prevents degradation while maintaining adequate solubility for injection, directly resolving the contradiction between bioavailability and chemical stability.
Solution Approach 2:
The patent uses disodium edetate (EDTA) as an intermediary stabilizing agent in the formulation. EDTA chelates metal ions that would otherwise catalyze degradation of fosnetupitant, acting as a protective mediator that enables the drug to remain stable in injectable form while maintaining bioavailability.
2Quantity of substance
If surfactants are added to maintain solubility, then solubility is improved, but safety deteriorates due to potential harm from additives
Solution Approach 1:
The patent extracts or removes harmful surfactant additives from the formulation by relying on pH adjustment and chelating agents instead. This eliminates the safety concerns associated with surfactants while maintaining adequate solubility of fosnetupitant through alternative mechanisms.
Solution Approach 2:
The patent changes the formulation parameters by using pH adjustment (to pH 7.0-10.0) and chelating agents (disodium edetate) to maintain solubility without requiring surfactants. This parameter change approach achieves solubility while avoiding the harmful effects of surfactant additives.
3Quantity of substance
If fosnetupitant concentration is increased, then efficacy is improved, but solubility control becomes unpredictable due to environmental variations
Solution Approach 1:
The patent establishes specific parameter ranges for pH (7.0-10.0, preferably 7.5-9.5) and uses fixed concentrations of stabilizing agents (disodium edetate at 0.05-0.9 mg/mL) to create a controlled formulation environment. These parameter specifications make solubility predictable and reliable even at higher fosnetupitant concentrations (2.3-30 mg/mL).
Solution Approach 2:
Disodium edetate acts as a stabilizing intermediary that buffers the formulation against environmental variations. By chelating metal ions and stabilizing the chemical environment, EDTA makes the solubility behavior of fosnetupitant more predictable and less sensitive to external conditions.
4Stability of the object's composition
If pH is adjusted to maintain stability, then chemical integrity is improved, but solubility may deteriorate
Solution Approach 1:
The patent identifies and applies an optimal pH range (pH 7.0-10.0, preferably pH 7.5-9.5) that simultaneously maximizes both chemical integrity and solubility of fosnetupitant. This parameter optimization resolves the contradiction by finding the pH window where the drug is both stable and sufficiently soluble for injection.
Solution Approach 2:
Disodium edetate serves as a mediating agent that enhances solubility within the stabilized pH range. The chelating agent works synergistically with pH adjustment to maintain both chemical integrity and adequate solubility, preventing the trade-off from becoming a limiting factor.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide stable, soluble, and safe injectable solutions that maintain chemical integrity and prevent unwanted conversion to netupitant, ensuring effective treatment of diseases mediated by the NK-1 receptor.
Implementation Method 1
disodium edetate to ensure stability and solubility, avoiding degradation
Implementation Method 2
Lyophilized and liquid formulations of fosnetupitant are developed
Data Source
AI summary
Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.